Disparities in emergency contraceptive metabolism dictate efficacy
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 3R01HD105866-02S1
Grant search
Key facts
Disease
Severe Acute Respiratory Syndrome (SARS)Start & end year
2022.02025.0Known Financial Commitments (USD)
$336,431Funder
National Institutes of Health (NIH)Principal Investigator
PROFESSOR ALISON EDELMANResearch Location
United States of AmericaLead Research Institution
OREGON HEALTH & SCIENCE UNIVERSITYResearch Priority Alignment
N/A
Research Category
Vaccines research, development and implementation
Research Subcategory
Adverse events associated with immunization
Special Interest Tags
N/A
Study Type
Non-Clinical
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Adolescent (13 years to 17 years)Adults (18 and older)
Vulnerable Population
Women
Occupations of Interest
Unspecified
Abstract
Project Summary Half the population will experience menstruation, is experiencing menstruation, or did experience menstruation. Menstruation occurs for approximately a week each month for 40 years - a substantial amount of one's lifetime is spent menstruating. Menstrual health (cycle and menses length, regularity, and volume/flow) is a key patient-reported outcome beyond its importance as a general indicator of health and fertility. Menstrual health outcomes are not routinely included in clinical trials and have not been a consideration for vaccine trials. Numerous reports of menstrual disturbances following COVID-19 vaccination, the complete absence of evidence, and the lack of attention on this gender-specific issue contributes to vaccine hesitancy, causes public mistrust and directly impacts preventable morbidity and mortality. Our preliminary data is the first prospective population-level data to establish baselines for COVID-19 vaccine exposure (dose 1 and 2) and menstrual-related outcomes. No other prospective population level dataset exists with regard to the impact of any vaccine on the menstrual cycle. Our large prospective cohort was established as part of a time limited NICHD supplement (R01HD089957 PI Edelman) "COVID19 vaccination and Menstruation" which ended June 2022. The overall objective for this application, in response to the Notice of Special Interest " Emerging and Existing Issues of Coronavirus Disease 2019 (COVID-19) Research Related to the Health and Well-Being of Women, Children and Individuals with Physical and/or Intellectual Disabilities" (NOT-HD-22-002), is to continue utilizing our unique large cohort to further understand the impact of COVID-19 vaccine exposure on the resolution of cycle disturbances 6 months post-vaccine, in key subpopulations like adolescents and contraceptive users, and with additional doses of vaccine ('boosters'). We have the datasets and access to additional data collection to expand our analyses beyond our supplement grant aims. The continuation of the prospective data set also enables us to rapidly respond to an ever-changing public health emergency. Our team has received the ongoing commitment of two leading online menstrual cycle tracking platforms with the built-in user approval to provide this de- identified data for research purposes plus the ability to survey these users to obtain additional data.